These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30146405)

  • 21. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.
    Dubey AP; Faridi MMA; Mitra M; Kaur IR; Dabas A; Choudhury J; Mukherjee M; Mishra D
    Hum Vaccin Immunother; 2017 Sep; 13(9):2032-2037. PubMed ID: 28509605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.
    Diaz C; Dentico P; Gonzalez R; Mendez RG; Cinquetti S; Barben JL; Harmon A; Chalikonda I; Smith JG; Stek JE; Robertson A; Caulfield MJ; Biasio LR; Silber JL; Chan CY; Vessey R; Sadoff J; Chan IS; Matthews H; Wang W; Schlienger K; Schödel FP;
    Vaccine; 2006 Nov; 24(47-48):6875-85. PubMed ID: 17050042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
    Pan HX; Qiu LX; Liang Q; Chen Z; Zhang ML; Liu S; Zhong GH; Zhu KX; Liao MJ; Hu JL; Li JX; Xu JB; Fan Y; Huang Y; Su YY; Huang SJ; Wang W; Han JL; Jia JZ; Zhu H; Cheng T; Ye XZ; Li CG; Wu T; Zhu FC; Zhang J; Xia NS
    Lancet Infect Dis; 2024 Aug; 24(8):922-934. PubMed ID: 38614117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix).
    Kreth HW; Lee BW; Kosuwon P; Salazar J; Gloriani-Barzaga N; Bock HL; Meurice F
    BioDrugs; 2008; 22(6):387-402. PubMed ID: 18998756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
    Choi UY; Kim KH; Lee J; Eun BW; Kim DH; Ma SH; Kim CS; Lapphra K; Tangsathapornpong A; Kosalaraksa P; Oberdorfer P; Kim HM; Shin SM; Kang JH
    Vaccine; 2021 Mar; 39(12):1758-1764. PubMed ID: 33627245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
    Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults.
    Paradis EM; Tikhonov O; Cao X; Kharit SM; Fokin A; Platt HL; Banniettis N
    Hum Vaccin Immunother; 2021 Nov; 17(11):4177-4182. PubMed ID: 34473594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents.
    Paradis EM; Tikhonov O; Cao X; Kharit SM; Fokin A; Platt HL; Wittke F; Jotterand V
    Hum Vaccin Immunother; 2021 Nov; 17(11):4183-4189. PubMed ID: 34702124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
    Gilderman LI; Lawless JF; Nolen TM; Sterling T; Rutledge RZ; Fernsler DA; Azrolan N; Sutradhar SC; Wang WW; Chan IS; Schlienger K; Schödel F; Silber JL;
    Clin Vaccine Immunol; 2008 Feb; 15(2):314-9. PubMed ID: 18077611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
    Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
    Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M
    Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.
    Gatchalian S; Tabora C; Bermal N; Leboulleux D; Desauziers E
    Am J Trop Med Hyg; 2004 Mar; 70(3):273-7. PubMed ID: 15031516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immunogenicity and safety of VARIVAX™ New Seed Process (NSP) in children.
    Senders SD; Bundick ND; Li J; Zecca C; Helmond FA
    Hum Vaccin Immunother; 2018 Feb; 14(2):442-449. PubMed ID: 29087781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.
    Faust SN; Le Roy M; Pancharoen C; Weber MAR; Cathie K; Behre U; Bernatoniene J; Snape MD; Helm K; Medina Pech CE; Henry O; Baccarini C; Povey M; Gillard P
    BMC Pediatr; 2019 Feb; 19(1):50. PubMed ID: 30732648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.